HTFL Medical Technology · AI healthcare · Software medtech · Recent IPO · Thesis updated July 14, 2026

Heartflow must prove it is more than FFRCT

Heartflow is a commercial AI medtech company built around the CCTA plus Heartflow pathway for coronary artery disease.
Most revenue comes from pay-per-click fees when doctors order and review a Heartflow analysis.
FFRCT Analysis is still the core product, at 98% of total cumulative revenue as of March 31, 2026.
The platform story depends on Plaque Analysis, PCI Navigator, and the planned 2027 Plaque Tracker launch.
The company lost $116.8 million in 2025 and had a $1.1 billion accumulated deficit at year-end.

01 Running thesis

A focused bet on heart CT

Heartflow wants to make coronary artery disease easier to diagnose without putting a tube into the heart. Doctors start with a coronary CT angiography scan, often called CCTA. Heartflow then uses software and AI to help show blood flow, narrowings, and plaque in the heart arteries.

The bull case is simple. If more doctors use CCTA first, and if Heartflow becomes the default add-on, each new case can turn into high-margin software revenue. The company also wants to sell more than one analysis per patient over time.

The hard part is that the company is still mostly one product. Heartflow FFRCT Analysis represented 98% of total cumulative revenue as of March 31, 2026. Plaque Analysis is early, PCI Navigator launched in April 2026, and Plaque Tracker is not expected until 2027.

So the next year matters. Investors need proof that Plaque Analysis and PCI Navigator can add real usage, not just product names. Without that proof, Heartflow stays a promising but deeply unprofitable single-product medtech software story.

May 2026→The Q1 2026 filing confirmed PCI Navigator launched in April 2026, which supports the platform plan. The view stayed balanced because FFRCT Analysis still represented 98% of total cumulative revenue as of March 31, 2026.

Mar 2026→The 2025 annual filing added Plaque Tracker as a planned 2027 product and refreshed the loss picture. Heartflow had a $1.1 billion accumulated deficit at year-end, so the pipeline update did not remove the funding and profitability risk.

Nov 2025▲Q3 revenue rose to $46.3 million from $32.9 million in the year-earlier quarter. The upgrade was limited because FFRCT concentration stayed at 98% and the accumulated deficit reached about $1.1 billion.

Sep 2025→The initial post-IPO view set up Heartflow as a fast-growing AI software medtech company with a pay-per-click model. The same filing showed a 98% FFRCT revenue concentration and about a $1.0 billion accumulated deficit.

02 Business model

Paid each time doctors click

Heartflow makes money mainly on a usage model. Each time a physician chooses to review Heartflow FFRCT Analysis, Plaque Analysis, or both, the company recognizes a fee when it delivers the requested analysis.

This can be a strong model if volumes rise. Software revenue can scale without building a factory for each new case. Hospitals and imaging centers also do not need to buy a large device from Heartflow to start using the service.

The weak point is payment. Heartflow depends on reimbursement, which means insurers, Medicare coding rules, and hospital billing policies matter a lot. A lower rate, slower approvals, or confusing coverage could hurt usage even if the technology works.

The other weak point is adoption. Doctors must trust the workflow and change how they manage chest pain and coronary artery disease. New clinical guidelines can help, but they do not force every doctor to change quickly.

03 Product portfolio

From one engine to a platform

Cash cow

Heartflow FFRCT Analysis

This is the commercial foundation. It estimates blood flow from a CCTA scan and helps doctors see whether a narrowing is likely to matter.

Growth engine

Heartflow Plaque Analysis

This product assesses coronary plaque, including how much plaque is present and what type it is. It is still early in commercialization, so usage growth is a key proof point.

Steady

Heartflow RoadMap Analysis

RoadMap is a workflow visualization tool. It supports the platform but is not a standalone growth engine in the current thesis.

Option

Heartflow PCI Navigator

PCI Navigator launched in April 2026. It is meant to help plan revascularization, which means opening or bypassing blocked heart arteries.

Option

Plaque Tracker

Plaque Tracker is expected in 2027. It would compare later CCTA scans with earlier scans to see whether plaque is getting better or worse over time.

04 Business segments

Revenue is still almost all FFRCT

Heartflow FFRCT Analysis98%modest

Other platform products2%growing fast

The mix uses Heartflow's disclosure that FFRCT Analysis was 98% of total cumulative revenue as of March 31, 2026. The remaining 2% is grouped as other platform products because the filings do not give a finer split.

05 Risk factors

What could break the story

Single-product dependence

High impact · High odds

FFRCT Analysis made up 98% of total cumulative revenue as of March 31, 2026. That means the company is still exposed to one main use case, one main workflow, and one main payment path. If FFRCT growth slows before Plaque Analysis scales, the platform thesis weakens fast.

We watchFFRCT share of revenue and any separate Plaque Analysis revenue or usage disclosure.

Reimbursement pressure

High impact · Medium odds

Heartflow depends on third-party payment rates and coding policies. If Medicare, private insurers, or hospital billing rules become less favorable, doctors may order fewer analyses. A pay-per-click model works best only when payment is clear and repeatable.

We watchMedicare coding updates, commercial coverage policies, and management comments on average reimbursement.

Slow doctor adoption

High impact · Medium odds

Heartflow needs doctors to use CCTA plus Heartflow as part of their normal coronary artery disease workflow. Clinical evidence and guidelines may help, but practice patterns can change slowly. If hospitals do not train teams or change ordering habits, product launches may not become revenue.

We watchCase volume growth, new customer additions, and management comments on guideline-driven adoption.

Losses keep funding risk alive

High impact · Medium odds

Heartflow lost $116.8 million in fiscal 2025. It also had an accumulated deficit of $1.1 billion as of December 31, 2025. If losses stay large while growth slows, the company may need more capital on terms that hurt shareholders.

We watchQuarterly net loss, operating cash burn, and cash runway language in filings.

New products do not attach

Medium impact · Medium odds

The platform case depends on doctors using more than FFRCT. Plaque Analysis is early, PCI Navigator only launched in April 2026, and Plaque Tracker is planned for 2027. If these products do not attach to existing FFRCT users, Heartflow may not get the larger revenue per patient that bulls expect.

We watchDisclosures on Plaque Analysis adoption, PCI Navigator usage, and bundled orders per CCTA case.

06 Quick answers

In one breath

What does Heartflow actually sell?

Heartflow sells cloud-based software analyses for coronary artery disease. A doctor orders an analysis after a CCTA heart scan, and Heartflow returns information about blood flow, plaque, and treatment planning.

Why is FFRCT so important for HTFL?

FFRCT Analysis is the product that built the business. It represented 98% of total cumulative revenue as of March 31, 2026, so growth and payment for that product still drive the company.

What is the biggest thing to watch over the next year?

Watch whether Plaque Analysis and PCI Navigator gain real use. If they add revenue on top of FFRCT, Heartflow starts to look more like a multi-product platform.

Is Heartflow profitable?

No. The company reported a $116.8 million net loss for fiscal 2025 and an accumulated deficit of $1.1 billion at December 31, 2025.